• Foundation
  • About 18 min
  • 5 practice questions

Biotechnology in medicine: genetically engineered insulin and gene therapy

Explain why recombinant therapeutics are safer, how Eli Lilly made human insulin from separate A and B chains in E. coli, and how gene therapy was first used for ADA deficiency.

If something looks wrong, please tell us.

By the end of this lesson you can

  • Explain the advantages of recombinant therapeutics over products from non-human sources.
  • Describe the structure of insulin and the role of the C peptide.
  • Explain how human insulin was produced in E. coli in 1983.
  • Define gene therapy and describe the treatment of ADA deficiency.

Recombinant DNA technology has had a huge impact on healthcare by making it possible to mass-produce safe and more effective therapeutic drugs. Because recombinant therapeutics are identical to human proteins, they do not trigger the unwanted immune responses common with similar products taken from animals, and they are free from the risk of infection carried by such sources.

Why insulin needed biotechnology

People with diabetes may need regular insulin. Earlier, insulin was extracted from the pancreas of slaughtered cattle and pigs. Animal insulin is slightly different from human insulin, and some patients developed allergies or other reactions to this foreign protein. A bacterium that makes human insulin could supply as much as needed. Insulin is a protein, so it cannot be swallowed as a tablet: it would be digested by proteases in the gut, so it is injected.

Structure and maturation of insulin

Mature insulin has two short polypeptide chains, chain A and chain B, linked by disulphide bridges. In mammals, including humans, insulin is made as a pro-hormone, pro-insulin, which has an extra stretch called the C peptide. During maturation the C peptide is removed, leaving A and B joined by disulphide bonds. The main challenge in making insulin by rDNA techniques was getting it assembled into this mature form.

Maturation of pro-insulin (simplified)

  1. Pro-insulin Single chain: B chain, C peptide and A chain.
  2. C peptide removed Processing cuts out the C peptide.
  3. Mature insulin A and B chains held together by disulphide bridges.

Human insulin from E. coli (1983)

In 1983, Eli Lilly, an American company, prepared two DNA sequences corresponding to the A and B chains of human insulin and introduced them into **plasmids of E. coli. The chains were produced separately, extracted, and then combined by creating disulphide bonds** to form human insulin. This route side-stepped the problem of processing pro-insulin, and the product is identical in structure to natural human insulin.

Making human insulin by rDNA technology

  1. Two DNA sequences One for chain A, one for chain B.
  2. Plasmids in E. coli Each sequence cloned and expressed in bacteria.
  3. Separate chains A and B chains produced and extracted separately.
  4. Combine Disulphide bonds formed to give human insulin.

Gene therapy

Gene therapy is a collection of methods for correcting a gene defect diagnosed in a child or embryo. Genes are inserted into a person's cells and tissues to treat a disease: a normal gene is delivered to take over the function of, and compensate for, the non-functional gene. Viruses that naturally insert their genetic material into host cells are used as vectors.

The first clinical gene therapy was given in 1990 to a 4-year-old girl with adenosine deaminase (ADA) deficiency. ADA is crucial for the immune system, and the disorder is caused by deletion of the ADA gene. Some children can be helped by bone marrow transplantation, others by enzyme replacement therapy (injections of functional ADA), but neither is completely curative.

  1. Lymphocytes are taken from the patient's blood and grown in culture outside the body.
  2. A functional ADA cDNA is introduced into them using a retroviral vector.
  3. The engineered lymphocytes are returned to the patient.
  4. Lymphocytes are not immortal, so the patient needs periodic infusions of engineered cells.
  5. If the ADA gene from marrow cells is introduced into cells at early embryonic stages, it could be a permanent cure.

ADA gene therapy: patient's lymphocytes + functional ADA cDNA (retroviral vector) → returned to patient; repeated because lymphocytes are not immortal.

Worked example 1: counting insulin's amino acids

Human insulin's A chain has 21 amino acids and its B chain has 30 (standard values). Step 1: total in mature insulin = 21 + 30 = 51 amino acids. Step 2: Eli Lilly's method needed one DNA sequence per chain; with 3 bases per codon, the coding regions for the chains alone hold 21 × 3 = 63 and 30 × 3 = 90 bases, a total of 153 bases (not counting start and stop signals). Answer: 51 amino acids, coded by 153 bases across the two sequences.

Worked example 2: why repeated infusions?

A child treated by ADA gene therapy improves but needs further treatment months later. Reasoning: (1) the corrected gene was put into mature lymphocytes; (2) these cells have a limited life and are not immortal; (3) as they die, the number of ADA-producing cells falls. Conclusion: periodic infusions of engineered lymphocytes are needed. Putting the gene into cells at an early embryonic stage, from which all later cells descend, could cure the condition permanently.

Key takeaways: recombinant therapeutics are identical to human proteins, so they avoid immune reactions and infection risk. Insulin is chains A and B joined by disulphide bridges; it is made as pro-insulin with a C peptide that is removed. Eli Lilly (1983) made the A and B chains separately in E. coli and joined them. Gene therapy delivers a normal gene to replace a faulty one; the first case (1990) treated ADA deficiency by putting ADA cDNA into the patient's lymphocytes with a retroviral vector.

Check your understanding

  1. 1. Which part of pro-insulin is removed during its maturation into insulin?

    1. Chain A
    2. Chain B
    3. The disulphide bridges
    4. The C peptide
    Show answer

    Answer: D. Pro-insulin contains an extra stretch, the C peptide, which is cut out during maturation. Mature insulin is chains A and B joined by disulphide bridges.

  2. 2. How did Eli Lilly produce human insulin in 1983?

    1. By producing chains A and B separately in E. coli and joining them by disulphide bonds
    2. By extracting insulin from pig pancreas
    3. By injecting the insulin gene into human pancreas
    4. By growing human pancreatic cells in a bioreactor
    Show answer

    Answer: A. Two DNA sequences, for the A and B chains, were put into E. coli plasmids. The chains were produced separately, extracted and combined by forming disulphide bonds.

  3. 3. Why did some patients react to insulin from cattle and pigs?

    1. It contained the C peptide
    2. It was injected instead of swallowed
    3. It is a foreign protein that can cause allergy or other reactions
    4. It was made by bacteria
    Show answer

    Answer: C. Animal insulin differs slightly from human insulin, so the body may treat it as foreign and react with allergy or other responses. Recombinant human insulin is identical to the natural molecule.

  4. 4. In the first clinical gene therapy for ADA deficiency, the functional ADA cDNA was introduced into

    1. the patient's liver cells inside the body
    2. the patient's lymphocytes grown in culture
    3. bacteria that were then injected
    4. a fertilised egg
    Show answer

    Answer: B. Lymphocytes from the patient's blood were grown outside the body, given functional ADA cDNA using a retroviral vector, and returned to the patient.

  5. 5. Assertion (A): A patient treated by ADA gene therapy using lymphocytes needs periodic infusions. Reason (R): The genetically engineered lymphocytes are not immortal.

    1. A is true but R is false
    2. Both A and R are true, and R is the correct explanation of A
    3. Both A and R are true, but R is not the correct explanation of A
    4. A is false but R is true
    Show answer

    Answer: B. The engineered lymphocytes have a limited lifespan, so as they die the treatment must be repeated with fresh engineered cells. R explains A.

Privacy · Terms · Refunds · Delivery